SlideShare a Scribd company logo
1 of 19
CASE PRESENTATION
ON
RHEUMATOID ARTHRITIS,
POLYARTHRITIS
My patient was a 35 year old female from
female ward of general medicine department.
I.P NO. : 51979
D.O.A : 26.11.15
SUBJECTIVE
REASON FOR ADMISSION : c/o abdominal discomfort,
joint pains. Vomiting past one month.
PAST MEDICAL HISTORY : Patient is steroid
dependent(can’t survive without these tablets)
not k/c/o DM,HTN
PAST MEDICATION HISTORY : on regular medication
past 10 years. T. Dexamethasone 0.5mg
T.Phenyl butazone
KNOWN ALLERGIES : Nil
SMOKER : No
ALCOHOLIC : No
TOBACCO IN ANY FORM : No
MARITAL STATUS : Married
OBJECTIVE
LABORATORY INVESTIGATIONS:
Blood Pressure, Cell Blood Count, Renal Function Test.
GENERAL INVESTIGATION :
Patient is conscious, weak, afebrile, poorly built. She is
steroid dependent from past 10 years.
LABORATORY REPORTS
ELECTROLYTES
Date 26-11-15 27-11-15
Blood Pressure 110/70 110/70
Electrolytes Normal value(mEq/L) Patient’s value(mEq/L)
Sodium 130-150 134
Potassium 3.5-5.8 4.42
Chloride 98-100 106
BLOOD COUNTS
CELLS NORMAL VALUE PATIENT VALUE
HEAMOGLOBIN
(g/dl)
M 12-16
F 11-14
10
TLC(cells/cumm) 5000-10000 9500
PLATELETS 1-3 lakh
POLYMORPHS 40-60 65
LYMPHOCYTES 20-30 27
BASOPHILS 0-1 00
EOSINOPHILS 1-4 04
MONOCYTES 1-2 04
RENAL FUNCTION TEST
Normal Value Patient Value
UREA(mg%) 15-45 61
URIC ACID(mg%) F 2-5
M 2-7
CREATININE(mg%) 0.6-1.4 2.6
ASSESSMENT
 Patient was diagnosed with Arthritis, Polyarthritis.
 Patient was steroid dependent from past 10 years.
 Patient had vomiting since one month.
 Patient has abnormal urea and creatinine value.
Urea - 61 mg%
Creatinine - 2.6 mg%
S.No TRADE NAME GENERIC
NAME
FREQU
ENCY
DAYS
01 Inj.Pantop IV
(40mg)
Pantoprazole
sodium
1-0-1 26/11/15 to 29/11/15
02 Inj.Emest (4mg) Ondansetron 1-1-1 26/11/15 to 29/11/15
03 T.Dolo(650mg) Paracetamol 1-1-1 26/11/15 to 27/11/15
04 T.Dexamethasone
(0.5mg)
Dexamethasone 1-0-1/2 26/11/15 to 29/11/15
05 T.TRP Tremadol +
Paracetamol
1-0-1 27/11/15 to 29/11/15
06 T.HCQ(200mg) Hydroxychloroqui
ne sulphate
1-0-0 27/11/15 to 29/11/15
TREATMENT PLAN
S.No. TRADE NAME GENERIC
NAME
FREQUE
NCY
DAYS
07 Pirox(40mg) Piroxicam 1-0-1 26/11/15
08 IVF 10NS Normal
saline
50ml/hr 26/11/15 to 29/11/15
DAY 1
• Patient had vomiting hence was very weak.
• Normal saline IVF was given to compensate
electrolyte loss.
• Renal function test report showed some
abnormalities in urea and serum creatinine
level.
• Inj.Pantop, Inj.Emeset, T. Dolo and
Dexamethasone, Normal saline, Piroxicam was
started.
• Blood pressure was normal.
DAY 2
• Patient now had less episodes of vomiting.
• Piroxicam was stopped.
• T.TRP, T.HCQ was started as she still had
complance of sever joint pain.
• All other medications were continued as per the
treatment chart.
• Blood pressure was recorded as normal.
DAY 3
• No episodes of vomiting was noticed.
• Emeset was continued to prevent vomiting due
to side effects of other drugs(dexamethasone,
tramadol, piroxicam)
• Patient started showing positive signs to the
treatment given.
• Medications continued as per the treatment
chart.
DAY 4
• Patient feels better.
• Medications continued as per the treatment
chart.
DRUG INTERRACTION
• HCQ-ONDANSETRON : MAJOR
Concurrent use of HCQ and QT prolonging
agents may result in increased risk of QT
prolongation.
• ONDANSETRON-TRP : MODERATE
Concurrent use of ondansetron and tramadol
may result in reduced efficacy of tramadol.
• Piroxicam, dexamethasone, tramadol, pantop,
hydroxychloroquine sulfate are contraindicative
in pregnant and lactating mothers.
PHARMACIST INTERVENSION
SUGGESSIONS TO PHYSICIAN:
• Emeset should not be given with HCQ and Tramadol.
• Drug duplication to be checked.
• Phenylbutazone has to be discontinued as it has major side
effect i.e kidney damage.(refer renal function test report)
SUGGESSIONS TO PATIENT:
• Inform physician in case of any side effects.
• Donot discontinue Dexamethasone until directed by a
physician as it has unpleasant withdrawal symptoms.
• Increase intake of calcium rich food.
• Take the medication properly as it will improve the quality
of life.
DISCHARGE CHART
 No discharge medication is available
rheumatoud arthritis and polyarthritis  ppt

More Related Content

Similar to rheumatoud arthritis and polyarthritis ppt

Empty sella presentation oncall duty .pptx
Empty sella presentation oncall duty .pptxEmpty sella presentation oncall duty .pptx
Empty sella presentation oncall duty .pptx
HamadAlablani2
 
Case Presentation on Diabetes Mellitus complications
Case Presentation on Diabetes Mellitus complicationsCase Presentation on Diabetes Mellitus complications
Case Presentation on Diabetes Mellitus complications
ShivankAgrawal5
 
Choriocarcinoma management in a patient with superimposed malaria and typhoid
Choriocarcinoma management in a patient with superimposed malaria and typhoidChoriocarcinoma management in a patient with superimposed malaria and typhoid
Choriocarcinoma management in a patient with superimposed malaria and typhoid
pharmben
 
Anti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case StudyAnti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case Study
velspharmd
 

Similar to rheumatoud arthritis and polyarthritis ppt (20)

Soap format on dvt
Soap format on dvtSoap format on dvt
Soap format on dvt
 
Gastrocon 2016 - Drug Induced Liver Disease
Gastrocon 2016 - Drug Induced Liver DiseaseGastrocon 2016 - Drug Induced Liver Disease
Gastrocon 2016 - Drug Induced Liver Disease
 
Empty sella presentation oncall duty .pptx
Empty sella presentation oncall duty .pptxEmpty sella presentation oncall duty .pptx
Empty sella presentation oncall duty .pptx
 
Hepatoma.pptx
Hepatoma.pptxHepatoma.pptx
Hepatoma.pptx
 
Seizure
Seizure Seizure
Seizure
 
Saf presentation
Saf presentationSaf presentation
Saf presentation
 
SOAPping MI
SOAPping MISOAPping MI
SOAPping MI
 
Case Presentation on Diabetes Mellitus complications
Case Presentation on Diabetes Mellitus complicationsCase Presentation on Diabetes Mellitus complications
Case Presentation on Diabetes Mellitus complications
 
Endocrine causes of hypertension
Endocrine causes of hypertension Endocrine causes of hypertension
Endocrine causes of hypertension
 
Mi
MiMi
Mi
 
199563394 case-study-dengue
199563394 case-study-dengue199563394 case-study-dengue
199563394 case-study-dengue
 
A case study on Pangastritis with pancreatitis
A case study on Pangastritis with pancreatitis A case study on Pangastritis with pancreatitis
A case study on Pangastritis with pancreatitis
 
Choriocarcinoma management in a patient with superimposed malaria and typhoid
Choriocarcinoma management in a patient with superimposed malaria and typhoidChoriocarcinoma management in a patient with superimposed malaria and typhoid
Choriocarcinoma management in a patient with superimposed malaria and typhoid
 
Anti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case StudyAnti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case Study
 
CKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. GawadCKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. Gawad
 
D.G.F. CME CASE STUDY DISCUSSION Abnormal Uterine Bleeding
D.G.F. CME CASE STUDY DISCUSSIONAbnormal Uterine BleedingD.G.F. CME CASE STUDY DISCUSSIONAbnormal Uterine Bleeding
D.G.F. CME CASE STUDY DISCUSSION Abnormal Uterine Bleeding
 
D.G.F. CME CASE STUDY DISCUSSION Abnormal Uterine Bleeding
D.G.F. CME CASE STUDY DISCUSSIONAbnormal Uterine BleedingD.G.F. CME CASE STUDY DISCUSSIONAbnormal Uterine Bleeding
D.G.F. CME CASE STUDY DISCUSSION Abnormal Uterine Bleeding
 
Undifferentiated schizophrenia
Undifferentiated schizophreniaUndifferentiated schizophrenia
Undifferentiated schizophrenia
 
E053026029
E053026029E053026029
E053026029
 
Thrombus everywhere
Thrombus everywhereThrombus everywhere
Thrombus everywhere
 

Recently uploaded

Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 
Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.
MateoGardella
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
QucHHunhnh
 
An Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdfAn Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdf
SanaAli374401
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
Chris Hunter
 

Recently uploaded (20)

fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writing
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
An Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdfAn Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdf
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
 
Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 

rheumatoud arthritis and polyarthritis ppt

  • 2. My patient was a 35 year old female from female ward of general medicine department. I.P NO. : 51979 D.O.A : 26.11.15
  • 3. SUBJECTIVE REASON FOR ADMISSION : c/o abdominal discomfort, joint pains. Vomiting past one month. PAST MEDICAL HISTORY : Patient is steroid dependent(can’t survive without these tablets) not k/c/o DM,HTN PAST MEDICATION HISTORY : on regular medication past 10 years. T. Dexamethasone 0.5mg T.Phenyl butazone
  • 4. KNOWN ALLERGIES : Nil SMOKER : No ALCOHOLIC : No TOBACCO IN ANY FORM : No MARITAL STATUS : Married
  • 5. OBJECTIVE LABORATORY INVESTIGATIONS: Blood Pressure, Cell Blood Count, Renal Function Test. GENERAL INVESTIGATION : Patient is conscious, weak, afebrile, poorly built. She is steroid dependent from past 10 years.
  • 6. LABORATORY REPORTS ELECTROLYTES Date 26-11-15 27-11-15 Blood Pressure 110/70 110/70 Electrolytes Normal value(mEq/L) Patient’s value(mEq/L) Sodium 130-150 134 Potassium 3.5-5.8 4.42 Chloride 98-100 106
  • 7. BLOOD COUNTS CELLS NORMAL VALUE PATIENT VALUE HEAMOGLOBIN (g/dl) M 12-16 F 11-14 10 TLC(cells/cumm) 5000-10000 9500 PLATELETS 1-3 lakh POLYMORPHS 40-60 65 LYMPHOCYTES 20-30 27 BASOPHILS 0-1 00 EOSINOPHILS 1-4 04 MONOCYTES 1-2 04
  • 8. RENAL FUNCTION TEST Normal Value Patient Value UREA(mg%) 15-45 61 URIC ACID(mg%) F 2-5 M 2-7 CREATININE(mg%) 0.6-1.4 2.6
  • 9. ASSESSMENT  Patient was diagnosed with Arthritis, Polyarthritis.  Patient was steroid dependent from past 10 years.  Patient had vomiting since one month.  Patient has abnormal urea and creatinine value. Urea - 61 mg% Creatinine - 2.6 mg%
  • 10. S.No TRADE NAME GENERIC NAME FREQU ENCY DAYS 01 Inj.Pantop IV (40mg) Pantoprazole sodium 1-0-1 26/11/15 to 29/11/15 02 Inj.Emest (4mg) Ondansetron 1-1-1 26/11/15 to 29/11/15 03 T.Dolo(650mg) Paracetamol 1-1-1 26/11/15 to 27/11/15 04 T.Dexamethasone (0.5mg) Dexamethasone 1-0-1/2 26/11/15 to 29/11/15 05 T.TRP Tremadol + Paracetamol 1-0-1 27/11/15 to 29/11/15 06 T.HCQ(200mg) Hydroxychloroqui ne sulphate 1-0-0 27/11/15 to 29/11/15 TREATMENT PLAN
  • 11. S.No. TRADE NAME GENERIC NAME FREQUE NCY DAYS 07 Pirox(40mg) Piroxicam 1-0-1 26/11/15 08 IVF 10NS Normal saline 50ml/hr 26/11/15 to 29/11/15
  • 12. DAY 1 • Patient had vomiting hence was very weak. • Normal saline IVF was given to compensate electrolyte loss. • Renal function test report showed some abnormalities in urea and serum creatinine level. • Inj.Pantop, Inj.Emeset, T. Dolo and Dexamethasone, Normal saline, Piroxicam was started. • Blood pressure was normal.
  • 13. DAY 2 • Patient now had less episodes of vomiting. • Piroxicam was stopped. • T.TRP, T.HCQ was started as she still had complance of sever joint pain. • All other medications were continued as per the treatment chart. • Blood pressure was recorded as normal.
  • 14. DAY 3 • No episodes of vomiting was noticed. • Emeset was continued to prevent vomiting due to side effects of other drugs(dexamethasone, tramadol, piroxicam) • Patient started showing positive signs to the treatment given. • Medications continued as per the treatment chart.
  • 15. DAY 4 • Patient feels better. • Medications continued as per the treatment chart.
  • 16. DRUG INTERRACTION • HCQ-ONDANSETRON : MAJOR Concurrent use of HCQ and QT prolonging agents may result in increased risk of QT prolongation. • ONDANSETRON-TRP : MODERATE Concurrent use of ondansetron and tramadol may result in reduced efficacy of tramadol. • Piroxicam, dexamethasone, tramadol, pantop, hydroxychloroquine sulfate are contraindicative in pregnant and lactating mothers.
  • 17. PHARMACIST INTERVENSION SUGGESSIONS TO PHYSICIAN: • Emeset should not be given with HCQ and Tramadol. • Drug duplication to be checked. • Phenylbutazone has to be discontinued as it has major side effect i.e kidney damage.(refer renal function test report) SUGGESSIONS TO PATIENT: • Inform physician in case of any side effects. • Donot discontinue Dexamethasone until directed by a physician as it has unpleasant withdrawal symptoms. • Increase intake of calcium rich food. • Take the medication properly as it will improve the quality of life.
  • 18. DISCHARGE CHART  No discharge medication is available